$PBYI 20% hike alone will propel sales much higher for Q4. Next year launch in 25 countries including China. This drug increased sales 600% yoy in Q4 2018 from launch. It’s almost breaking even. It should come pretty close to cash flow positive this Q4. Any big pharma could scoop this for $35 a share and get their money back in 4 years. It has a pretty clean balance sheet as well. Sales are just taking a breather here before going higher again.